Italia markets close in 10 minutes

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
In data: 05:40PM BST. Mercato aperto.

Biocartis Group NV

Generaal de Wittelaan 11 B
Mechelen 2800
Belgium
32 1 563 26 00
https://www.biocartisgroupnv.be

Settore/i
Settore
Impiegati a tempo pieno526

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Piet HouwenChief Operating OfficerN/DN/D1968
Mr. Roger MoodyChief Executive OfficerN/DN/DN/D
Mr. George A. CardozaCFO & Head of Service DeliveryN/DN/D1962
Mr. Benoit DevogelaereChief Technology OfficerN/DN/D1981
Mr. Geert Maertens Ph.D.Chairman of Scientific Advisory Board & Chief Scientific OfficerN/DN/DN/D
Renate DegraveHead of IR & Corporate CommunicationsN/DN/DN/D
Mr. Erik Vossenaar Ph.D.Senior Vice-President of Corporate Development and StrategyN/DN/D1973
Ms. Susy SpruytHead of People & OrganizationN/DN/D1968
Dr. Erwin SablonHead of R&D and Alliance ManagementN/DN/D1965
Mr. Reginald Van GenechtenHead of Manufacturing & Supply ChainN/DN/D1966
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Governance aziendale

L'ISS Governance QualityScore di Biocartis Group NV al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.